AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02931539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: Maribavir 400 milligrams (mg) (2x200 mg tablets) will be administered twice daily for 8 weeks.
Study NCT02931539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ganciclovir
Description: Ganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
Study NCT02931539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: Valganciclovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
Study NCT02931539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Foscarnet
Description: Foscarnet as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
Study NCT02931539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cidofovir
Description: Cidofovir as per the investigator's prescribed dosing regimen will be administered for 8 weeks.
Study NCT01658878 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01658878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study NCT01658878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02297893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dexterity training program (HOMEDEXT)
Description: The dexterity training program contains 7 exercises which focus on improving fine motor skills.
Study NCT01658878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Study NCT03310515 — intervention group
Intervention type: BEHAVIORAL
Intervention: Risk reduction counseling
Description: Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
Study NCT03310515 — intervention group
Intervention type: OTHER
Intervention: Social harm interview
Description: Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
Study NCT03310515 — intervention group
Intervention type: OTHER
Intervention: Computer-Assisted Self Interviewing technique
Description: Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
Study NCT03048279 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.~Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail.
Study NCT02297893 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Theraband training program
Description: The Theraband training program contains 7 exercises which focus on improving upper limb strength
Study NCT01119040 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Natural Orifice Translumenal Endoscopic Surgery
Description: Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery.
Study NCT04241003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartDrive Mx2+
Description: Rear-mounted power assist
Study NCT02512796 — intervention group
Intervention type: DRUG
Intervention: Gadolinium contrast dye
Description: Gadolinium contrast dye administered during MRI
Study NCT04460027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Woebot Substance Use Disorder
Description: Woebot Substance Use Disorder is an automated conversational agent, available through a smartphone application, that delivers evidence-based psychotherapeutics, empathy, and emotional health psychoeducation.
Study NCT00447421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)~Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles
Study NCT00447421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
Study NCT00447421 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
Study NCT03714841 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CRP
Description: Knowledge of CRP value
Study NCT03714841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CRP
Description: Knowledge of CRP value
Study NCT02471417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary nitrate
Description: 140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
Study NCT02471417 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
Study NCT05895851 — intervention group
Intervention type: RADIATION
Intervention: head and neck radiation
Description: RON and non-RON: nasopharyngeal carcinoma patients recieved head and neck radiation; Normal: normal individuals.
Study NCT00576914 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study NCT02284867 — intervention group
Intervention type: OTHER
Intervention: immunohistochemistry study
Description: After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
Study NCT00576914 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: recombinant human endostatin
Description: recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
Study NCT02739412 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subjects will self-administer low dose IL-2 as subQ injection (0.30 MIU per meter squared body surface area) for 4 weeks.
Study NCT02928640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ClariCore System
Description: Data collection to build the prostrate tissue classification algorithm.
Study NCT03270787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
Study NCT03270787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound danshen dripping pills
Description: Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
Study NCT04121910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: On Study Day 1 and Study Day 18, savolitinib will be administered as single dose after a high-fat, high-calorie breakfast
Study NCT04121910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Twice daily on first day of dosing (Study Day 15) followed by once daily for 4 days (Study Day 16 - Study Day 19) administered 1 hour before any breakfast (and 1 hour before dinner on Study Day 15)
Study NCT01893177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflexal V
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
Study NCT01738035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEFECON
Description: All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
Study NCT01738035 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
Study NCT02417623 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application group
Description: Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
Study NCT04507750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Carmelizumab: Intravenous infusion of a fixed dose of 200 mg in 30 minutes (not less than 20 minutes, not more than 60 minutes), once every 3 weeks, continuous administration until the disease progresses, the patient If death or intolerable toxicity occurs, medication for up to 1 year; Apatinib mesylate tablets: The initial dose is 250 mg, administered once a day, and continue to be administered. If there is a grade 3 to 4 adverse reaction, it should be administered once every other day.
Study NCT00729430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3 Fatty Acids (Fish Oil Supplements)
Description: 4 grams of omega-3 fatty acids taken orally once per day for 6 months
Study NCT02197195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate Milk
Study NCT02197195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit Drink
Study NCT02197195 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT01770223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: boceprevir
Study NCT01770223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PegIFN-2b
Study NCT01770223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Study NCT03679091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
Study NCT03679091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low-dose ticagrelor
Description: low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).
Study NCT03679091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
Study NCT03679091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).
Study NCT03373643 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OSA screening
Description: Full night polysomnography
Study NCT03935815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: 30 mL of 0.25% ropivacaine will be administered on both the right and left sides with a 20 gauge, 4 inch ultrasound needle using a SonoSite ultrasound machine with a linear transducer probe. The tip of the ultrasound needle will be placed posterior to the quadratus lumborum muscle (QL2) made in the plane between the quadratus lumborum muscle and thoracolumbar fascia.
Study NCT03935815 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: A sham procedure with a superficial 22 gauge needle stick will be performed without injectate.
Study NCT02113566 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1000mg
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
Study NCT02113566 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen 1000mg
Description: Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
Study NCT02372032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: percutaneous lumbar discectomy
Description: process percutaneous lumbar discectomy
Study NCT02372032 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous lumbar discectomy
Description: process percutaneous lumbar discectomy
Study NCT02372032 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: percutaneous intradiscal ozone injection
Study NCT01232907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine
Description: L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
Study NCT03150797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin
Study NCT03150797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo
Study NCT03307850 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation During Exercise and Stress
Description: Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.~Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study.
Study NCT04104542 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction
Description: on-line training on the website = www.palousemindfulness.com
Study NCT04104542 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Healthy Lifestyle
Description: Diet and Exercise
Study NCT04737135 — intervention group
Intervention type: OTHER
Intervention: Non intervention
Description: Patients without intervention
Study NCT04537663 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guérin (BCG)
Description: Participants in the intervention group will be vaccinated with the licensed BCG vaccine (Danish strain 1331, SSI, Denmark) using the standard vaccination technique for this vaccine (intradermal injection in the left upper arm).
Study NCT04537663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intradermal injection of sterile 0.9% NaCl.
Study NCT00729430 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets taken orally once per day for 6 months
Study NCT04733755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beauty Image
Description: 1.97g/package; 2 packages one day for 8 weeks
Study NCT04733755 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control; 1.97g/package; 2 packages one day for 8 weeks
Study NCT04557345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Determination of cytokines
Description: Subsequently, a blood sample will be taken from which the processing will be as follows: 6 ml of peripheral blood will be taken in tubes with a yellow cap and inert gel and clot retractor, immediately afterward it will be placed on ice, it will be transported to the laboratory where it will be centrifuged at 2500 rpm for 15 minutes at 4 degrees centigrade, immediately afterward 500 µl of serum will be aliquoted and stored at minus 75 ° C until later analysis. The general methodology for sandwich ELISA will be used.
Study NCT02987153 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Kypho-IORT
Description: The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
Study NCT00270634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voclosporin
Description: voclosporin 0.4, 0.6, 0.8 mg/kg po BID
Study NCT00270634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: tacrolimus 0.05 mg/kg po BID
Study NCT06152458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Patients in the intervention group (G1) (n=23) received the combined vitamin therapy: IV vitamin C (1.5 g every 6 hours administered as an infusion over 30 to 60 minutes and mixed in a 100- mL solution of normal saline), hydrocortisone (100 mg in bolus-100 mg in perfusor up to 60 min (200mg 24h),), and thiamine (200 mg every 12 hours administered as an infusion over 30 to 60 minutes and mixed in a 100-mL solution of normal saline) for 3 days.
Study NCT03461445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients will be randomized to receiving Envarsus instead of IR Tacrolimus
Study NCT03461445 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR Tacrolimus
Description: Patients will be randomized to receiving IR Tacrolimus instead of Envarsus
Study NCT00421304 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Motavizumab
Description: A single IV dose of motavizumab 30 mg/kg or 100 mg/kg will be administered on Day 0 of the study.
Study NCT03067311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-CAT
Description: I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
Study NCT03067311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as usual defined by participant clinician at OASIS clinic.
Study NCT00421304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single IV dose of placebo matched to motavizumab will be administered on Day 0 of the study.
Study NCT01367054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg tablet
Study NCT01367054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glifage
Description: 500 mg tablet
Study NCT02476045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil,leucovorin,panitumumab
Description: Maintenance treatment (ARM A)
Study NCT02476045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panitumumab
Description: Maintenance treatment (ARM B)
Study NCT02476045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Description: Induction treatment
Study NCT02476045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab
Description: Induction treatment